Abstract：
Parkinson\'s disease (PD) is a progressive and disabling neurodegenerative disease that rapidly worsens and results in premature mortality if left untreated. Although levodopa is the gold standard treatment for PD globally, its accessibility and affordability are severely limited in low- and middle-income countries worldwide. In this scenario, Mucuna pruriens (MP), a leguminous plant growing wild in tropical regions, emerges as a potential alternative or adjunct to levodopa-based medications due to its cost-effectiveness and global natural availability. Recent studies have demonstrated that MP can significantly ameliorate motor symptoms, although tolerability may vary. The proposition that MP could play a pivotal role in providing affordable and symptomatic relief for PD in low- and middle-income countries is grounded in its promising therapeutic profile, yet caution is warranted until more comprehensive data on the long-term safety and efficacy of MP become available. This manuscript summarizes the knowledge gained about MP by the authors, focusing on how to cultivate, store, and provide it to patients in the safest and most effective way in clinical trials. We aim to increase clinical trials investigating its safety and efficacy in PD, before promoting individual use of MP on a global scale, particularly in countries where availability and affordability of levodopa-based medications is still limited.
摘要：
帕金森病（PD）是一种进行性和致残的神经退行性疾病，如果不及时治疗，会迅速恶化并导致过早死亡。尽管左旋多巴是全球PD治疗的黄金标准，在全世界的低收入和中等收入国家，其可及性和可负担性受到严重限制。在这种情况下，Mucunapruriens（MP），一种在热带地区生长的豆科植物，由于其成本效益和全球自然可用性，成为左旋多巴药物的潜在替代品或辅助药物。最近的研究表明，MP可以显着改善运动症状，虽然耐受性可能有所不同。MP可以在低收入和中等收入国家为PD提供负担得起的有症状的缓解方面发挥关键作用的主张是基于其有希望的治疗方案，然而,在获得有关MP长期安全性和有效性的更全面数据之前,仍需谨慎行事.这份手稿总结了作者获得的关于MP的知识，专注于如何培养，store,并在临床试验中以最安全和最有效的方式提供给患者。我们的目标是增加临床试验，调查其在PD中的安全性和有效性，在全球范围内推广个人使用MP之前，特别是在基于左旋多巴的药物的可获得性和可负担性仍然有限的国家。
